Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

M Lotem; T Peretz; O Drize; Z Gimmon; D Ad El; R Weitzen; H Goldberg; I Ben David; D Prus; T Hamburger

doi:10.1038/sj.bjc.6600251

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Identifier:nobleid.org/w1/20260515/C7F68DB5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C7F68DB5.svg?ark=w1%2F20260515%2FC7F68DB5)](https://nobleid.org/work/w1/20260515/C7F68DB5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Identifier:nobleid.org/w1/20260515/C7F68DB5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C7F68DB5.svg?ark=w1%2F20260515%2FC7F68DB5)](https://nobleid.org/work/w1/20260515/C7F68DB5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work